|Budget Amount *help
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|Outline of Final Research Achievements
The purpose of the study was to test if sorafenib can decrease the incidence of hepatocellular carcinoma (HCC) induced by diethyl nitrosoamine (DEN) with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). Otsuka Long-Evans Tokushima Fatty (OLETF) was usued as a model of NAFLD/NASH. As a result, the incidence of HCC was decreased in sorafenib-treated groups irrespective of the presence of fatty liver. However, less number of animals survived after treatment of sorafenib as compared to sorafenib non-treated group. Although sorafenib can prevent occurrence of HCC, some of the NAFLD/NASH animals could not survive sorafenib related side effects probably due to their susceptibility to infection.